CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C IN PATIENTS WITH PULMONARY TUBERCULOSIS
Abstract
Background. Tuberculosis when combined with parenteral viral hepatitis is a major medical and social concern for public health worldwide due to the widespread prevalence of these diseases, resulting in large economic costs associated with chronicity of the infections, the development of formidable complications and adverse outcomes. Objective – to determine clinical and laboratory characteristics of chronic hepatitis C (CHC) in patients with pulmonary tuberculosis. Material and methods. The paper presents the results of a comprehensive examination and dynamic observation of 69 patients co-infected with both chronic hepatitis C and pulmonary tuberculosis, whose average age was 43.8±4.22 years. Results. Clinical course of CHC in patients with pulmonary tuberculosis is characterized by latent state in 97.1±2.0% of patients with mild clinical manifestations. The most common manifestation was asthenovegetative syndrome (92.7±3.0%) due to tuberculous intoxication. The concomitant tuberculous process influenced the dynamics of biochemical parameters, more significant deviations being observed after 3 months of anti-tuberculosis therapy (p<0.05). Conclusions. The accompanying tuberculous process adversely affects clinical and laboratory parameters in the natural history of chronic hepatitis C.References
1.Asratjan AA, Solovev DV, Rodina OV, Garmash JuJu, Litvinov VI, Musina EE, Mardanly SG, Kazarjan SM, Kjuregjan KK, Popova OV, Rusakova EV. Klinikojepidemiologicheskie osobennosti gepatitov B i C u bolnyh tuberkulezom legkih [Clinical and Epidemiological Features of Hepatitis B and C in Patients with Pulmonary Tuberculosis]. Jepidemiologija i vakcinoprofilaktika [Epidemiology and Vaccinal Prevention]. 2013;6(73):20-27. (Russian).
2. Ahundova IM, Mamedov MK, Dadasheva AJe, Rzaeva HR. Bolnye tuberkulezom, inficirovannye virusami gepatitov B i C, kak osobyj klinicheskij kontingent pacientov [Tuberculosis patients infected with hepatitis B and C viruses as a special clinical contingent of patients]. Tuberkulez i bolezni legkih [Tuberculosis and Lung Diseases]. 2011;88(8):51-54. (Russian).
3. Vsemirnaja organizacija zdravoohranenija. Bjulleten programmy VOZ po borbe s tuberkulezom v Rossijskoj Federacii. Vol. 7. Moskva, 2008. 36 p. (Russian).
4. Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, Yang PC. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis. 2010;14(5):616-621.
5. Gombos CG. Pop M, Rajnoveanu R. The main causes which lead to immediate and belated failure in tuberculosis. Europ. Resp. J. 2005;26(Suppl 40):944.
6. Galickij LA, Zareckij BV, Lebedinec AI. Virusnyj gepatit B vo ftiziatricheskoj praktike. Bolshoj Celevoj Zhurnal o tuberkuleze. 1999;4:10-12. (Russian).
7. Guryljova MJe. Tuberkuljoz i zabolevanija pecheni. In: Perelman MI, editor. Ftiziatrija. Nacionalnoe rukovodstvo. Moskva: GJeOTAR-Media; 2007. p. 349-351. (Russian).
8. Ivashkin VT, Maevskaja MV, Zharkova MS, Tihonov IN, Fedosina EA, Pavlov ChS. Algoritmy diagnostiki i lechenija v gepatologii. Мoskva: MEDPress-inform; 2016. 163 p. (Russian).
9. Onishchenko GG, Dementeva LA. Spread of hepatitis virus AS a threat to national security. Zhurnal mikrobiologii, jepidemiologii i immunobiologii. [Journal of Microbiology, Epidemiology and Immunobiology]. 2003;4:93-99.
10. Petrenko TI, Filimonov PN. Hronicheskij virusnyj gepatit u pacienta s tuberkuljozom ljogkih. In: Perelman MI, editor. Tuberkuljoz v Rossii. God 2007. Materialy VIII Rossijskogo sezda ftiziatrov; 2007 Jun. 6-8; Moskva. Moskva: Ideja; 2007. p. 412. (Russian).
11. Pokrovskij VI, Pak SG, Briko NI, Danilkin BK. Infekcionnye bolezni i jepidemiologija. Moskva: GJeOTAR-Media; 2013. 1008 p. (Russian).
12. Rzaeva NR, Mamedov MK, Mamedbekov JeN, Dadasheva AJe. Infekcii, vyzvannye virusami gepatitov B i C u bolnyh tuberkuljozom ljogkih: osobennosti rasprostranenija i znachenija. Mir virusnyh gepatitov. 2008;5:22-25. (Russian).
13. Solovev DV. Jepidemiologicheskie osobennosti virusnyh gepatitov B i C u bolnyh tuberkulezom legkih i taktika ih profilaktiki [master’s thesis]. Мoskva (Russian); 2012. 23 p. (Russian).
14. Shahgildjan IV, Jasinskij AA, Mihajlov MI, Ershova ON, Huhlovich PA, Hasanova VA, Lytkina IN, Shulakova NI, Romanenko VV, Patlusova VV, Kolenova TV, Oorzhak ND, Korshunova GS, Klimenko SM. Hronicheskie gepatity v Rossijskoj Federacii [Chronic hepatitis in the Russian Federation]. Jepidemiologija i infekcionnye bolezni [Epidemiology and Infectious Diseases]. 2008;6:12-15. (Russian).
15. Alter MJ, Mast EE, Moyer LA, Margolis HS. Hepatitis С. Infect. Dis. Clin. North Am. 1998;12(1):13-26. https://doi.org/10.1016/s0891-5520(05)70405-0.
16. Damen M, Reesink HW. Hepatitis В the actual problem public health. The Netherlands J. of Med. 1995;46(3):A11-A14.
17. Sherlock S, Dooley JS. Diseases of the liver and biliary system. 10th ed. New York: Wiley; 1997. p. 289-296.
18. Arjamkina OL, Savonenkova LN, Ruzov VI, Midlenko VI, Gnoevyh VV, Razin VA, Gimaev RH. Hronicheskij gepatit pri legochnom, vnelegochnom i abdominalnom tuberkuljoze [The chronic hepatitis under pulmonary, extra-pulmonary and abdominal tuberculosis]. Klinicheskaja laboratornaja diagnostika [Russian Clinical Laboratory Diagnostics Journal]. 2017;62(8):462-467. (Russian).
19. Mishin VJu, Chukanov VI, Vylengzhanin SV. Jeffektivnost standartnogo rezhima himioterapii pri lechenii vpervye vyjavlennyh bolnyh destruktivnym tuberkuljozom ljogkih s bakteriovydeleniem. Tuberkulez i bolezni legkih [Tuberculosis and Lung Diseases]. 2001;78(7):13-17. (Russian).
20. Pritulina JuG, Fil GV, Kornienko SV, Plohotnjuk NV. Novye podhody k patogeneticheskoj terapii bolnyh, stradajushhih tuberkulezom i virusnym gepatitom C [New approaches to pathogenetic therapy of patients suffering with tuberculosis and viral hepatitis C]. Jeksperimentalnaja i klinicheskaja gastrojenterologija [Experimental and Clinical Gastroenterology Journal]. 2018;7:97-101. (Russian).
21. Talanova OS. Kliniko-diagnosticheskaja ocenka komorbidnogo techenija hronicheskogo virusnogo i tuberkuleznogo gepatita [master’s thesis]. Uljanovsk (Russian); 2013. 138 p. (Russian).
22. Gramada D, Enache M, Gramada A. Hepatic disorders in patients with pulmonary tuberculosis. Europ. Resp. J. 2005;26(Suppl 40):2660.
23. Iravani YM, Masjedi MR, Yazdanpanach M. Antituberculosis drug-related liver dysfunction hepatitis B, C and role of age as a risk factor. Intern. J. Tuberc. And Lung Dis. 2001;5(11):118.
24. Shigetoh E, Murakami I, Yokosaki Y, Kurimoto N. Treatment Outcomes of Multidrug-Resistant Tuberculosis -Comparison Between Success and Failure Cases. Kekkaku [Tuberculosis]. 2001;76(12):723-28. (Japanese).
